skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

5 Total results for product and free and sample content found

Medtech Insight

US Election 2020: Almost All House Members Backed By Industry PAC Dollars Retain Seats

By Sue Darcey 16 Jun 2022

US Election 2020 PAC dollars

Out of 31 US House incumbents supported by high amounts of medtech industry political action committee (PAC) dollars, only one – Chrissy Houlahan of Pennsylvania – lost in last week’s election.

Topic US Election 2020 Policy & Regulation Legislation

Generics Bulletin

California Plans To Create Own Generics Label

By Aidan Fry 27 Nov 2020

California_Plans_To_Create_Own_Generics_Label

California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

Topic Legislation Policy & Regulation

Medtech Insight

US Election 2020: Industry Loses Three Favored Incumbents In Battle For Senate Control

By Sue Darcey 18 Nov 2020

US Election senate battle

A few of the US Senate candidates favored and given tens of thousands of dollars by industry have lost their battles for re-election

Topic US Election 2020 Legislation

Pink Sheet

Biopharma Needs A Deal On Drug Pricing As Shield Against Possible Democrat Wins - BIO's Greenwood

By Cathy Kelly 21 Sep 2020

US Election Drug Pricing Shielding

Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.

Topic US Election 2020 Drug Pricing Legislation

Pink Sheet

Mylan/Biocon's Insulin Glargine Would Get A Respite Under US Budget Legislation

By Cathy Kelly 18 Dec 2019

MylanBiocons_Insulin_Glargine_Would_Get

Bill addresses ‘dead zone’ for pending applications for protein products transitioning to biologic status; generic and brand industries each win in different legislative provisions: inclusion of the CREATES Act, and a revised definition for ‘biologics’ that includes chemically synthesized polypeptides.

Topic Biosimilars Legislation

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: